The safety of prolonged indomethacin therapy.
The purpose of this study was to describe the fetal and newborn safety profile of prolonged indomethacin treatment during pregnancy. A retrospective cohort of 124 pregnant women treated with indomethacin was used to assess the outcomes of oligohydramnios, constriction of the ductus arteriosus, and composite neonatal morbidity. Eight patients (6.5%) developed ductal constriction and nine patients (7.3%) developed oligohydramnios. Composite morbidity occurred in 36 neonates (29%). Ductal constriction, oligohydramnios, and composite morbidity were not associated with duration of therapy, gestational age at start or stop of therapy, time between dosing and delivery, or dose regimen. Prolonged indomethacin therapy rarely is associated with ductal constriction and oligohydramnios.
Savage
Ashlyn H
AH
Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Anderson
Brenna L
BL
Simhan
Hyagriv N
HN
D000293:Adolescent; D000328:Adult; D015331:Cohort Studies; D064420:Drug-Related Side Effects and Adverse Reactions; D004373:Ductus Arteriosus / Q000187:drug effects; D004374:Ductus Arteriosus, Patent / Q000139:chemically induced; D005260:Female; D005865:Gestational Age; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D007752:Obstetric Labor, Premature / Q000188:drug therapy* / Q000517:prevention & control; D016104:Oligohydramnios / Q000139:chemically induced; D011247:Pregnancy; D011256:Pregnancy Outcome; D012189:Retrospective Studies; D015149:Tocolytic Agents / Q000009:adverse effects* / Q000627:therapeutic use
D015149:Tocolytic Agents; D007213:Indomethacin